Neurona Therapeutics
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf neural cell therapies to repair dysfunctional neural circuits underlying chronic disorders of the nervous system. Its pipeline is led by rezanecel (NRTX-1001), a first-in-class inhibitory neuron therapy for drug-resistant epilepsy. Founded by neuroscientists and stem cell pioneers at UCSF, the company was acquired by UCB in June 2026.
Acquired
Neurona Therapeutics has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
51–200
Total Funding
$347.48M
6 rounds
Latest Valuation
$0.72B
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalUCB announced completion of its acquisition of Neurona Therapeutics: $650M upfront plus up to $500M in milestones.
Neurona is now a wholly owned UCB company; no further private rounds expected.
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $347.48M across 6 rounds
Last updated 10-06-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Apr 3, 2025 | Series F | $102M | — | Not disclosed |
| Feb 8, 2024 | Series E | $120M | — | Viking Global Investors, Cormorant Asset Management |
| Jun 22, 2021 | Series D | $72M | — | UCB Ventures, The Column Group |
Prominent Investors
Leadership
Cory R. Nicholas
Co-Founder and Chief Executive Officer
Catherine Priest
Chief Development Officer
Gautam Banik
Chief Technology Officer
James Stutz
Chief Financial Officer and Chief Business Officer
Eduardo Dunayevich
Chief Medical Officer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.